{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:20:42Z","timestamp":1787030442323,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.3816\/clc.2005.n.028","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:08:44Z","timestamp":1221080924000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Single-Agent Gefitinib in Patients with Untreated Advanced Non\u2013Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial"],"prefix":"10.3816","volume":"7","author":[{"given":"David R.","family":"Spigel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily R.","family":"Burkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise A.","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melodie","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne F.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie R.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Scullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Bradof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Rubinsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Brierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Anthony","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLC.2005.n.028_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-5002(99)00017-3","article-title":"Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy","volume":"24","author":"Thongprasert","year":"1999","journal-title":"Lung Cancer"},{"key":"10.3816\/CLC.2005.n.028_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials","volume":"311","author":"Non-Small Cell Lung Cancer Collaborative Group","year":"1995","journal-title":"BMJ"},{"key":"10.3816\/CLC.2005.n.028_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2000.18.3.623","article-title":"Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooper ative Oncology Group trial","volume":"18","author":"Bonomi","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.3816\/CLC.2005.n.028_bib6","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0169-5002(95)00450-F","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument","volume":"12","author":"Cella","year":"1995","journal-title":"Lung Cancer"},{"key":"10.3816\/CLC.2005.n.028_bib8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.1986.4.5.702","article-title":"Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study","volume":"4","author":"Finkelstein","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib9","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1200\/JCO.1986.4.11.1604","article-title":"Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy","volume":"4","author":"O'Connell","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib10","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","article-title":"Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience","volume":"9","author":"Albain","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.1995.13.5.1221","article-title":"Prognostic factors for survival in advanced nonsmall-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. The European Lung Cancer Working Party","volume":"13","author":"Paesmans","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib12","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8","article-title":"Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma","volume":"92","author":"Sweeney","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CLC.2005.n.028_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLC.2005.n.028_bib14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib15","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2004.04.370","article-title":"Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES)","volume":"22","author":"Perrone","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLC.2005.n.028_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/annonc\/mdh087","article-title":"Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel","volume":"15","author":"Gridelli","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","article-title":"Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients","volume":"12","author":"Le Chevalier","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib19","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1023\/A:1013574413217","article-title":"Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?","volume":"12","author":"Soria","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2004.01.022","article-title":"Single-agent gefitinib as first-line therapy in patients with advanced non-small cell lung cancer: Washington University experience","volume":"45","author":"Kommareddy","year":"2004","journal-title":"Lung Cancer"},{"key":"10.3816\/CLC.2005.n.028_bib21","first-page":"633","article-title":"Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma","volume":"23","author":"Johnson","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.lungcan.2004.04.032","article-title":"Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced nonsmall-cell lung cancer","volume":"46","author":"Kaneda","year":"2004","journal-title":"Lung Cancer"},{"key":"10.3816\/CLC.2005.n.028_bib23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2004.08.158","article-title":"Bronchioloalveolar Pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Miller","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2005.n.028_bib24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.3816\/CLC.2005.n.028_bib25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411704004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411704004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:59:37Z","timestamp":1761505177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730411704004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S1525730411704004"],"URL":"https:\/\/doi.org\/10.3816\/clc.2005.n.028","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-Agent Gefitinib in Patients with Untreated Advanced Non\u2013Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLC.2005.n.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}